{"id":753622,"date":"2023-05-02T09:26:15","date_gmt":"2023-05-02T13:26:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/"},"modified":"2023-05-02T09:26:15","modified_gmt":"2023-05-02T13:26:15","slug":"elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/","title":{"rendered":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus"},"content":{"rendered":"<p>        <!--.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus<\/b><\/p>\n<p><i>Targeted single-dose monoclonal antibody is the first and only treatment for devastating dog disease<\/i><\/p>\n<p>GREENFIELD, Ind.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nElanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus \u2014 one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive care<sup>i<\/sup>. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 360px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg\" alt=\"First and only monoclonal antibody treatment that targets canine parvovirus. (Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">First and only monoclonal antibody treatment that targets canine parvovirus. (Photo: Business Wire)<\/p>\n<\/div>\n<p>\nWith an estimated 330,000 cases of canine parvovirus available for treatment in the U.S. annually<sup>ii<\/sup>, clinical trials demonstrate that the Canine Parvovirus Monoclonal Antibody single, intravenous dose delivers targeted efficacy in treating this deadly disease. The treatment can be administered to dogs eight weeks of age or older with canine parvovirus. The Canine Parvovirus Monoclonal Antibody treatment may provide a less intensive and more effective solution than supportive care alone by targeting the virus with single dose efficacy and a strong safety profile in healthy dogs.<\/p>\n<p>\n\u201cElanco is proud to bring to market this first-in-class treatment that will help save puppies lives, while alleviating the emotional and financial burden of both pet owners and veterinary care teams,\u201d said<b \/>Jeff Simmons, president and CEO, Elanco. \u201cWe\u2019re excited to bring our first monoclonal antibody treatment to market, reinforcing Elanco\u2019s commitment to pioneer new tools in spaces where there aren\u2019t existing options. We\u2019re committed to helping the world\u2019s pets live longer, healthier lives because we believe making life better for our pets makes life better.\u201d<\/p>\n<p>\nThe Canine Parvovirus Monoclonal Antibody is expected to begin shipping in the coming weeks, pending individual state approvals. Elanco will also continue to provide canine parvovirus education and resources to veterinarians, shelter owners and pet parents.<\/p>\n<p>\n\u201cToday\u2019s announcement is a game changer for pet owners and veterinarians,\u201d said Dr. Kristin Zersen, DVM, DACVECC, assistant professor of small animal emergency and critical care at Colorado State University Veterinary Teaching Hospital. \u201cParvovirus is an unpredictable disease that causes significant strain on pet owners and is labor intensive and stressful for shelters and veterinary clinic staff. It\u2019s lifechanging and industry-defining to be able to offer a proven solution to canine parvovirus that limits the need for hospitalization, reducing the impact this disease has on hundreds of thousands of dogs each year.\u201d<\/p>\n<p>\nThe conditional license approval\u2014granted by the USDA to effectively and safely meet an emergency situation, limited market or special circumstance\u2014of the first-ever targeted monoclonal antibody treatment for canine parvovirus bridges Elanco\u2019s expertise in both therapeutics and vaccines. In the treatment efficacy study, the Canine Parvovirus Monoclonal Antibody was proven effective in decreasing mortality associated with parvovirus infection.<sup>iii <\/sup>Treated dogs also had significantly faster times to resolution of the most-adverse effects of parvovirus including vomiting<sup>iv<\/sup>, meaning that they feel better faster and get home sooner.<\/p>\n<p>\nPrior to Elanco\u2019s Canine Parvovirus Monoclonal Antibody, the only treatment for the highly contagious canine parvovirus was supportive therapy, which can consist of 24\/7 care, multi-day hospitalization and emotional stress for the staff and pet owner with no guaranteed outcome and potentially high pet owner costs. In conjunction with its portfolio of innovative solutions, this announcement establishes Elanco\u2019s presence in the monoclonal antibody space and reinforces its commitment to helping pets live longer, healthier lives through its portfolio of innovative solutions.<\/p>\n<p>\nFor more information, please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmy.elanco.com%2Fus%2Fcampaign%2Fparvo&amp;esheet=53388907&amp;newsitemid=20230427005591&amp;lan=en-US&amp;anchor=FightParvo.com&amp;index=1&amp;md5=bc33eaba6833672cf027de818aff28b6\">FightParvo.com<\/a>.<\/p>\n<p><b>ABOUT ELANCO<\/b><\/p>\n<p>\nElanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we\u2019re driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose\u2122\u2013 all to advance the health of animals, people, the planet and our enterprise. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.elanco.com%2Fen-us&amp;esheet=53388907&amp;newsitemid=20230427005591&amp;lan=en-US&amp;anchor=www.elanco.com&amp;index=2&amp;md5=9b9a8e9b404dea4f9227375145c50bca\"><b>www.elanco.com<\/b><\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">______________________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>i<\/sup> Venn, E.C. et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. Journal of Veterinary Emergency and Critical Care. 27(1) 2017, 52-65. doi: 10.1111\/vec.12561.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>ii<\/sup> Elanco Animal Health. Data on File. VetSuccess Parvovirus Incidence Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>iii<\/sup> Elanco Animal Health. Data on File.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>iv<\/sup> Elanco Animal Health. Data on File.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a92023 Elanco or its affiliates. PM-US-23-0232.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230427005591r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Contact: Kathryn Grissom +1.317.273.9284 <a rel=\"nofollow\" href=\"mailto:kathryn.grissom@elancoah.com\">kathryn.grissom@elancoah.com<br \/>\n<\/a><br \/>Media Contact: Season Solorio +1.765.316.0233 <a rel=\"nofollow\" href=\"mailto:season.solorio@elancoah.com\">season.solorio@elancoah.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Indiana United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Consumer Infectious Diseases Pets Pharmaceutical Veterinary<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/704782\/3\/Elanco_logo_blue.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/3\/Vial.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">First and only monoclonal antibody treatment that targets canine parvovirus. (Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776720\/3\/Comparison_chart.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Advantages of Canine Parvovirus Monoclonal Antibody versus traditional treatments. (Graphic: Business Wire)<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776722\/3\/Treatment_chart.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Treatment efficacy study results illustrate targeted effectiveness of Canine Parvovirus Monoclonal Antibody. (Graphic: Business Wire)<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776723\/3\/Canine_Parvovirus_Header_with_Logo.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">(Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus Targeted single-dose monoclonal antibody is the first and only treatment for devastating dog disease GREENFIELD, Ind.&#8211;(BUSINESS WIRE)&#8211; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus \u2014 one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/ First and only monoclonal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753622","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus Targeted single-dose monoclonal antibody is the first and only treatment for devastating dog disease GREENFIELD, Ind.&#8211;(BUSINESS WIRE)&#8211; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus \u2014 one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/ First and only monoclonal &hellip; Continue reading &quot;Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T13:26:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus\",\"datePublished\":\"2023-05-02T13:26:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/\"},\"wordCount\":900,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230427005591\\\/en\\\/1776719\\\/4\\\/Vial.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/\",\"name\":\"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230427005591\\\/en\\\/1776719\\\/4\\\/Vial.jpg\",\"datePublished\":\"2023-05-02T13:26:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230427005591\\\/en\\\/1776719\\\/4\\\/Vial.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230427005591\\\/en\\\/1776719\\\/4\\\/Vial.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/","og_locale":"en_US","og_type":"article","og_title":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk","og_description":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus Targeted single-dose monoclonal antibody is the first and only treatment for devastating dog disease GREENFIELD, Ind.&#8211;(BUSINESS WIRE)&#8211; Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus \u2014 one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230427005591\/en\/ First and only monoclonal &hellip; Continue reading \"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-02T13:26:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus","datePublished":"2023-05-02T13:26:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/"},"wordCount":900,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/","name":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg","datePublished":"2023-05-02T13:26:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230427005591\/en\/1776719\/4\/Vial.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elanco-announces-breakthrough-treatment-for-deadly-canine-parvovirus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753622"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753622\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}